Substituted Cycloalkane Compounds for Selective ERβ Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current selective estrogen receptor modulators (SERMs) lack specificity for estrogen receptor beta (ERβ) and have carcinogenic side effects, providing minimal memory enhancement and increased cancer risk, necessitating the development of new ligands that selectively target ERβ for treating diseases associated with ER activity.
Innovation Solution
Substituted (4'-hydroxylphenyl)cycloalkane compounds are developed as selective agonists for ERβ, formulated as pharmaceutical compositions to treat diseases associated with ERβ activity, exhibiting specificity as ERβ agonists versus ERα agonists or antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current SERMs (tamoxifen, raloxifene) are used to treat ER-related diseases, then they provide tissue-specific estrogenic activity and have been safe and effective for breast cancer treatment, but they lack specificity for ERβ and have carcinogenic side effects with increased cancer risk
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (substituted (4'-hydroxylphenyl)cycloalkane compounds with specific X, Y, and R group configurations) that confer selective affinity for ERβ over ERα. This structural specificity enables the compound to exert estrogenic effects preferentially in ERβ-expressing tissues while minimizing activation of ERα in ERα-dominant tissues like breast and uterus, thereby reducing carcinogenic side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (substituents at positions 1-10 on the cycloalkane ring, different R groups, stereochemistry) to optimize ERβ selectivity. The compounds are designed with specific molecular weight ranges, hydrophobicity values, and spatial configurations that enhance binding affinity for ERβ while reducing off-target effects, thereby improving the safety profile
2Reliability
If current SERMs are used, then they provide some cognitive benefits, but they provide minimal memory enhancement
Solution Approach 1:
The patent applies parameter changes by optimizing molecular parameters to enhance penetration into the central nervous system and selective activation of ERβ in brain regions involved in memory and cognition. The compounds are designed with appropriate lipophilicity and molecular size to cross the blood-brain barrier, and with structural features that preferentially engage ERβ isoforms in the CNS, thereby maximizing cognitive and memory benefits
3Object-affected harmful factors
If selective ERβ agonists are developed, then they can provide CNS benefits with minimal side effects, but new ligands need to be developed with specific molecular structures and properties
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at defined positions on the cycloalkane ring (positions 1-10) to confer ERβ selectivity. Each substituent is strategically placed to interact with specific amino acid residues in the ERβ binding pocket, enabling selective agonism while maintaining reasonable structural simplicity for drug development
Solution Approach 2:
The patent employs universality by designing a core cycloalkane structure that can accommodate various substituents and modifications while maintaining ERβ selectivity. This modular approach allows a single core structure to serve multiple therapeutic indications (cancer prevention, cognitive enhancement, bone health, cardiovascular protection) by simply changing the substituent pattern, thereby reducing overall molecular complexity
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Disclosed are substituted (4'-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (ΕΚβ). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with ERβ activity, such as proliferative diseases and disorders and/or psychiatric diseases or disorders.